Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.
Yu C, Geng S, Yang B, Deng Y, Li F, Kang X, Bi M, Zhang F, Zhao Y, Pan W, Tian Z, Xu J, Zhang Z, Yu N, Duan X, Guo S, Sun Q, Li W, Tao J, Liu Z, Yin Y, Wang G.
Yu C, et al. Among authors: tao j.
Chin Med J (Engl). 2024 Jan 9. doi: 10.1097/CM9.0000000000002873. Online ahead of print.
Chin Med J (Engl). 2024.
PMID: 38192233